by NuWaveRx » Fri Aug 01, 2008 2:53 am
I echo Blir's statement concerning the financial potential of a drug like this--not only in patients with DM, but in any who is overweight. Believe me the holy grail for Big Pharma is not a cure for Breast Cancer or HIV, but a reliable and safe weight-loss drug. I don't have the biochem background Blir does, but from what I know of this line of drug investigation, it would have the potential to cause lipolysis in anyone--thus your true "fat burning" drug.
I think another concern is the possible safety issues with such a medication. Remember our true goal with treating DM is not to get someone's blood sugars under control, but to prevent the macrovascular (e.g. heart disease) and microvascular (e.g. kidney failure) complications that hyperglycemia plays a significant role in. IIRC these drugs would be similar in function to PPAR agonist drugs. The prototypical PPAR agonist (aiming to treat dyslipidemia) was pulled from the market before it even got started due an increased risk of heart attack in patients using them.
Finally, Max, recent data supports your contention that aggressive monitoring of blood sugars in DM 2 may not be beneficial:
Routine Self-Monitoring of Blood Glucose Counterproductive in Type 2 Diabetes
NEW YORK (Reuters Health) Apr 17 - Blood glucose monitoring by patients with type 2 diabetes not requiring insulin therapy provides no long-term health benefits and may in fact reduce patients' quality of life, according to two prospective randomized trials published in BMJ Online First on April 18.
A cost-utility analysis of self-monitoring based on data from the prospective Diabetes Glycaemic Education and Monitoring (DiGEM) trial. The study cohort included 453 patients with type 2 diabetes managed with diet or oral hypoglycemic agents alone, and who had an HbA1c level > 6.1%.
Subjects were randomized to usual care (n=152), less intensive self monitoring with advice to contact their doctor for interpretation of the results (n=150), or more intensive self-monitoring and training in interpreting the results (n=151). Patients in the intervention groups were instructed to measure their blood glucose levels three times daily on 2 days/week.
At 12 months, no difference was found in HbA1c levels between the groups after adjustment for baseline HbA1c levels. Responses to a health-related quality of life questionnaire revealed significant increases in the levels of anxiety and depression between baseline and the 12-month follow-up in the intervention groups.
Meanwhile, in the prospective Efficacy of Self Monitoring (ESMON) study, researchers in Northern Ireland compared outcomes among 184 patients with newly diagnosed type 2 diabetes randomized to self-monitoring or no monitoring. Those assigned to self-monitoring were asked to measure four fasting and four postprandial blood glucose levels each week.
Dr. Maurice J. O'Kane, at Altnagelvin Hospitals Health and Social Services Trust in Londonderry, and his team detected no significant differences between groups at any time during the 12-month trial in HbA1c values, episodes of hypoglycemia, or change in body mass index.
BMJ Online First 2008.